Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.33 |
| ▸ | TP53 | P04637 | 7/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3029553 | 0.90 | ADRB3 (0.32) | KCNA5ALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL3046589 | 0.82 | RECQL (0.35) | TP53ALDH1A1KMT2AHSD17B10KDM4E | |
| SCHEMBL13276124 | 0.79 | ALDH1A1 (0.35) | KCNA5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL3035669 | 0.77 | — | — | |
| SCHEMBL3029556 | 0.71 | CRY1 (0.40) | ALDH1A1GAATSHRHTT | |
| SCHEMBL2980473 | 0.70 | CYP2D6 (0.31) | TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL13276241 | 0.70 | ADRB3 (0.36) | ALDH1A1TSHRSMN1; SMN2ADRB1ADRB3 | |
| SCHEMBL3035537 | 0.68 | — | — | |
| SCHEMBL4951329 | 0.68 | PER2 (0.38) | — | |
| SCHEMBL3962539 | 0.68 | PER2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735304-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-01-07 | — | — | EP | claimed |
| US-7375114-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-05-20 | — | — | US | claimed |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2005-10-13 | — | — | US | claimed |
| US-9873692-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9630960-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160376264-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9353106-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150291580-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-8962653-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140163063-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-7763637-B2 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7728006-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7592355-B2 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | THERAVANCE, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1735304-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080176895-A1 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | ALFASIGMA S.P.A. (IT) | 2008-07-24 | — | — | US | disclosed |
| US-7375114-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070281970-A1 | Quinolinone-Carboxamide Compounds as 5-Ht4 Receptor Agonists | ALFASIGMA S.P.A. (IT) | 2007-12-06 | — | — | US | disclosed |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | ALFASIGMA S.P.A. (IT) | 2007-11-22 | — | — | US | disclosed |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | KCNA5 664/4885TP53 4762/4885ALDH1A1 2540/4885 |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | HTR4, HTR5A, HTR1A | KCNA5 669/4885TP53 4766/4885ALDH1A1 2360/4885 |
| US-20160376264-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | KCNA5 664/4885TP53 4762/4885ALDH1A1 2540/4885 |
| US-20150291580-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | KCNA5 664/4885TP53 4762/4885ALDH1A1 2540/4885 |
| US-20080176895-A1 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | HTR4, HTR5A, HTR1A | KCNA5 652/4885TP53 4767/4885ALDH1A1 2659/4885 |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | KCNA5 664/4885TP53 4762/4885ALDH1A1 2540/4885 |
| US-20070281970-A1 | Quinolinone-Carboxamide Compounds as 5-Ht4 Receptor Agonists | HTR4, HTR7, HTR3C | KCNA5 439/4885TP53 4144/4885ALDH1A1 2408/4885 |
| US-20140163063-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | KCNA5 664/4885TP53 4762/4885ALDH1A1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.